Clinical outcome of children on HAART at Police referral hospital, Addis Ababa, Ethiopia

Ethiopian Medical Journal

Volumn 47, Issue 2, 2009, Pages 159-164

  Memirie, Solomon Tessema ^a  

^a AAU   (Ethiopia)

Author keywords

Children; Efficacy; HAART; Safety

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG COMBINATION; ETHIOPIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; STATISTICS; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 77957300447     PISSN: 00141755     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AIDS in Ethiopia, 5th Report. Federal Ministry of Health, National HIV/AIDS Prevention and Control Office. June 2004.
2. Guidelines for use of antiretroviral drugs in Ethiopia, ministry of health, Jan 2005.
3. FMOH. sixth report, AIDS in Ethiopia. June 2006.
4. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004. 368:1236-43. (Pubitemid 39311344)
5. Pediatric HIV/AIDS care and treatment in Ethiopia: Result of a situational analysis. FMOH, ICAP. February 2006.
6. FMOH, Federal HIV/AIDS prevention and control office. Guidelines for pediatric HIV/AIDS care and treatment in Ethiopia. July 2007.
7. Scaling up antiretroviral therapy in resource-limited settings. Geneva: World health organization, 2004.
8. WHO Anthro 2005. Anthropometric calculator.
9. Siberry and Tessema. Immune reconstitution syndrome precipitated by bacille Calmette Guerin after initiation of antiretroviral therapy. Pediatr Infect Dis J, 2006;25:648-9.
10. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004;351:23-32. (Pubitemid 38857244)
11. Tindyebwa, D. et al. Hand book on pediatric AIDS in Africa, African network for the care of children affected by AIDS, revised edition, July 2006, p. 129.
12. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
13. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-34. (Pubitemid 41713744)
14. McConnel N, Byers R, Frederick T, et al. Trends in Antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 2005;38:488-94. (Pubitemid 40381559)
15. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with H1V-1. N Engl J Med 2001;345:1522-8. (Pubitemid 33144917)
16. Viani RM, Araneta MR, Deville JG, and Specter SA. Decrease in Hospitalization and mortality rates among children with Perinatally Acquired HIV Type 1 Infection Receiving highly active antiretroviral therapy. Clinical infectious diseases 2004;39:725-31. (Pubitemid 39180447)
17. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristic of hospitalized patients with HIV infection. AIDS 1999;13:415-8 (Pubitemid 29095105)
18. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:143-52. (Pubitemid 32595165)
19. Johnston AM, Valentine ME, Ottinger J, et al. Immune reconstitution in human immunodeficiency virus infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J, 2001;20:941-6. (Pubitemid 32952670)
20. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur J Med Res, 2005. 10(12):503-8. (Pubitemid 43009566)
21. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-9. (Pubitemid 29382462)
22. Kaufman GR, Perrin L, Pantaleo G, et al. CD4 T-lyinphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV cohort study. Arch Intern Med 203. 163(18):2187-95.
23. Messele T, Abdulkadir M, Fontanet A, et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopian compared with their Dutch counter parts. Ethiopian Medical Journal, 1999;37:89-96.
24. Kassa E, Rinke de Wit TF, Hailu E, et al. Evaluation of the world health organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. Ethiopian Medical Journal, 1999;37:67-75.
25. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med 2004;350:2471-80. (Pubitemid 38736544)